Key facts
- Imperative Care’s last known valuation is $1.6B (Jul 2024).
- It has raised $663.4M across 4 recorded rounds; the latest was Later Stage VC ($100.0M) in Mar 2026.
- Notable investors include D1 Capital Partners, Catalio Capital Management, Perceptive Advisors, Ally Bridge Group, Ascension Ventures — 20 tracked in total.
- Imperative Care has filed 6 Form Ds with the SEC since 2019, most recently Mar 2026 ($100.0M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Imperative Care
Funding rounds
4 roundsAbout Imperative Care
Operator of a commercial-stage medical technology company intended for researching, developing, and manufacturing to improve care for people with vascular diseases. The company focuses on addressing specific gaps in treatment and care to make an impact across the entire patient journey from detection through recovery for patients with ischemic and hemorrhagic stroke and transforms thrombectomy care for people suffering from devastating vascular diseases, including pulmonary embolism, enabling healthcare providers to evolve quality practices and elevate the standard of care.
- Industry
- Surgical Devices
- Sector
- Healthcare
- HQ
- Campbell, CA, United States
- Founded
- 2015
- Employees
- 374
- Website
- imperativecare.com/
- Ownership
- Privately Held (backing)
Imperative Care doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Imperative Care shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Imperative Care in its N-PORT filings yet. We sweep new filings monthly.